Purpose This study aimed at assessing the prognostic factors of resection of intrahepatic cholangiocarcinoma (IHCC), which remain unclear. Methods Among 70 patients with IHCC, who were admitted to our hospital between 1998 and 2011, 45 (64 %) underwent resection and 25 had unresectable tumors. Univariate and multivariate analyses were conducted retrospectively to assess the factors influencing survival of the patients who underwent resection. Results The median survival times of the patients who underwent resection versus those who did not were 16 months versus 9 months, respectively (P \ 0.001). Multivariate analysis identified residual tumor status (relative risk 4.12, P = 0.04) and pathological differentiation (relative risk 5.55, P = 0.04) as independent factors predicting survival. Patients who underwent R1 resection had a significantly higher rate of local recurrence than those who underwent R0 resection (P = 0.008). With R0 resection, there were no significant differences in patterns and rates of recurrence between patients with narrow (B5 mm) versus wide ([5 mm) surgical margins. Conclusions R0/1 resection and a well-differentiated tumor were found to be independent prognostic factors for long-term survival after IHCC resection. If R0 resection was achieved, the width of the negative surgical margin did not affect the patterns and rates of recurrence.
Introduction
Intrahepatic cholangiocarcinoma (IHCC) is the second most frequent primary liver cancer, but accounts for only 4.1 % of all patients with primary liver cancer, according to a nationwide survey conducted in Japan [1] . The most effective treatment for IHCC is potentially curative resection, with a 5-year survival rate of approximately 20 % [2] . One major reason for the dismal prognosis is the lack of predictive markers for the disease, but the effects of the surgical procedures used and other factors affecting the survival of patients with IHCC after resection have not been fully elucidated.
Several prognostic factors for IHCC have been reported. A few studies have identified lymph node metastasis as one of the most important factors [3] [4] [5] , while others have proposed positive surgical margins and intrahepatic metastasis as key factors predicting poor outcomes after surgical resection [6] . Serum tumor markers have also been recognized as important prognostic factors [7] [8] [9] [10] , although some authors have reported that these factors did not affect the survival of IHCC patients [11] . We conducted the current study to define the factors influencing prognosis after surgical resection, based on our 13-year experience of patients with IHCC.
Methods

Patients
The subjects of this retrospective study were 70 patients admitted to Kobe University Hospital, Japan, between July 1998 and April 2011, for management of peripheral IHCC. Peripheral IHCC was defined as a tumor that had developed from the intrahepatic bile duct at a site peripheral to the second branch. This study did not include patients with combined hepatocellular and cholangiocellular carcinoma or those with cholangiolocellular carcinoma. Prior to surgery, all patients provided informed consent to have relevant data from their medical records used in clinical studies, if appropriate.
Of the 70 patients, 15 had inoperable disease, based on radiologic examinations. The reasons for inoperability were multiple liver metastases (n = 2), lung metastasis (n = 2), locally invasive tumor (n = 7), and poor general condition (n = 4). The remaining 55 patients were scheduled for surgical resection; however, during surgery, 10 of these patients were found to have unresectable disease, such as peritoneal metastasis (n = 6), invasion of the inferior vena cava (n = 2), multiple liver metastases (n = 1), or severe adhesions after gastrectomy (n = 1). The resectability rate was 64.3 % (45/70).
Predictive factors were examined in 44 patients, excluding 1 patient who died during the postoperative stay in hospital. The following characteristics were obtained from medical records, then reviewed and analyzed: carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, number of tumors, tumor size (diameter), pathological differentiation, T category, N category, and residual tumor status. Tumor staging was based on the American Tumor Study Group modified Tumor-Node-Metastases (TNM) Staging Classification, 7th edition [12] .
Surgery for IHCC
Forty-five patients underwent surgical resection, at the time of which sampling of regional or paraaortic lymph nodes was routinely performed. N category was classified based on the histological result of sampling lymph nodes or imaging studies. Residual tumor status was defined as follows: R0 resection, no macroscopic or microscopic tumor remaining; R1 resection, microscopically positive surgical margins; and R2 resection, not all gross tumors removed.
After surgery, patients received regular clinical followup with blood chemistry, including the tumor markers CA 19-9 and CEA. They were examined for recurrence at 3-6 monthly intervals by computed tomography scans of the abdomen and lungs. Recurrence was diagnosed mainly based on the imaging studies.
Chemotherapy for IHCC
Following R0 or R1 resection, postoperative adjuvant chemotherapy was given to selected patients, who had poor prognostic factors such as lymph node metastasis. Patients with R2 resection were excluded from the analysis of adjuvant chemotherapy. We started treatment with gemcitabine (GEM) within 10 weeks after surgery. For this adjuvant therapy, six cycles of GEM were planned, with each 28-day cycle consisting of intravenous GEM administered at a dose of 1000 mg/m 2 on days 1, 8, and 15, and withdrawal of GEM on day 22. If adverse events of grade 3 or 4 were observed, the cycle was usually changed to biweekly scheduling. Adverse events were assessed according to the US National Cancer Institute Common Toxicity Criteria scale (version 2.0) [13] . Of the 39 patients who underwent R0 or R1 resection, 15 (38 %) received adjuvant chemotherapy with GEM.
Of the five patients who underwent R2 resection, two received GEM-based chemotherapy, one received 5-fluorouracil-based chemotherapy, and two received palliative care. For the 25 patients with unresectable disease, 17 received GEM-based chemotherapy, 1 underwent transcatheter arterial chemoembolization, and 7 received palliative care.
Statistical analysis
The v 2 test was used to compare categorical variables in the study patients with IHCC. Survival curves were constructed using the Kaplan-Meier method and the log-rank test was used to compare the curves. Cox proportional hazard models were used to estimate relative risks and 95 % confidence intervals. Multivariate analysis was performed for factors that were significantly associated with survival in univariate analysis. Differences were considered significant at P \ 0.05. Statistical analysis was performed using JMP software, 9th edition (SAS, Cary, NC, USA). Table 1 summarizes the patient characteristics. The 70 patients analyzed included 44 men and 26 women with a median age of 68 years. In terms of virus status, six patients were positive for anti-hepatitis C virus antibody (anti-HCV), five were positive for hepatitis B surface antigen (HBs-Ag), and two were positive for both anti-HCV and HBs-Ag. Indocyanine green (ICG) tests were performed for 27 patients and the mean retention rate of ICG 15 min after administration (ICG-R15) was 11.3 %. There were no patients with cirrhosis in this series.
Results
Patient characteristics
Of the 45 patients who underwent resection, 17 (38 %) had experienced the following symptoms: upper abdominal pain (n = 9), general fatigue (n = 3), and other symptoms such as anorexia, epigastric discomfort, epigastric tumor, weight loss, and jaundice (n = 5).
Surgical procedures and mortality
The surgical procedures are listed in Table 1 . Twentyeight patients underwent R0 resection, 12 underwent R1 resection, and 5 underwent R2 resection. Of the 12 patients who underwent R1 resection, there was residual tumor at the bile duct stump in 3 patients, in the liver parenchyma in 7 patients, and in both of these locations in 2 patients. One patient with R1 resection died of pneumonia during the postoperative stay, resulting in a hospital mortality rate of 2 % (1/45). The study analyses were performed using clinical data from the remaining 44 patients.
Tumor markers CEA and CA19-9 concentrations were measured in all except 1 of the 44 patients analyzed. CEA was elevated in 14 patients, with a median value of 3.2 ng/ml (range 0.8-1392 ng/ml; reference value \5 ng/ml). CA19-9 was elevated in 24 patients, with a median value of 52.8 U/ml (range 2-829,290 U/ml; reference value \37 U/ml). To examine the prognostic importance of CA19-9, patients were divided into two groups according to the CA19-9 cutoff point specified in a previous report, of C200 U/ml and \200 U/ml [14] . Of the 43 patients with tumor marker measurements, 21 had CA19-9 C200 U/ml. All of the patients with R2 resection had an elevated CA19-9 C200 U/ml.
Tumor characteristics
According to the morphologic classification of the Liver Cancer Study Group of Japan criteria, there were 38 patients with mass-forming type (MF), 2 with intraductal growth type (IG), 2 with MF ? IG type, and 2 with periductal infiltrating type IHCC. The mass-forming type was dominant and there were eight patients with multi-nodular tumors. The mean tumor diameter was 6.1 cm (range 1.8-15 cm). Pathologically, the tumors were diagnosed as well differentiated adenocarcinoma in 9 patients, moderately differentiated adenocarcinoma in 29 patients, poorly differentiated adenocarcinoma in 1 patient, adenosquamous cell carcinoma in 2 patients, and unknown differentiated carcinoma in 3 patients. Twenty-one patients had microscopic vascular invasion and 11 had lymph node metastasis. According to the TNM staging system, the overall stage was classified as I in 11 patients, II in 18 patients, III in 4 patients, and IV in 11 patients. Analyses of survival and recurrence
The median survival times of the patients who underwent resection versus those who did not undergo resection were 16 months versus 9 months, respectively, with a median observation period of 11 months (P \ 0.0001). The 5-year survival rate of the patients who underwent resection was 41.8 %, with one patient surviving [8 years, while the longest survival time among the patients who did not undergo resection was only 27 months ( Fig. 1 ).
Recurrence developed in 22 of the 39 (56 %) patients who underwent R0 or R1 resection. Univariate and multivariate analyses were performed using data from the 44 patients who underwent resection, excluding the R1 resection patient who died in hospital, for CEA and CA19-9 analyses. An additional patient without measurements was also excluded (Table 2) . Based on univariate analysis, CA19-9 \200 U/ml, well differentiated adenocarcinoma, T1 or T2 tumors, and R0 or R1 resection were significant prognostic factors. The N category did not have an impact on survival. We also examined the patients who did not undergo bile duct resection, because the efficacy of bile duct resection for lymphadenectomy was still controversial [2, 15] . We found the N category did not have an impact on survival (RR 1.45, P = 0.54). Multivariate analysis revealed that residual tumor status and pathological differentiation were the only variables significantly related to survival. GEM-based adjuvant chemotherapy did not improve either the cumulative or disease-free survival rates.
Next, we examined the cut-off point of the serum CA 19-9 level using the receiver operating characteristic (ROC) curve (Fig. 2a) . The cut-off point was 625 U/ml. The ROC curve was generated for the death during the observation period. The area under the ROC curve was 0.71. CA19-9 was over 625 U/ml in 14 patients. The 2-year survival rates of patients whose CA19-9 was \625 U/ml versus those whose CA19-9 was C625 U/ml were 82 and 0 %, respectively (Fig. 2b) . Figure 3 shows survival according to the residual tumor status. R0 resection tended to result in a better prognosis (cumulative survival) than R1 resection, but the difference was not significant (P = 0.18). The cumulative survival rate of patients who underwent R2 resection was worse than those of the patients who underwent R0 (P \ 0.0001) or R1 resection (P = 0.002) (Fig. 3a) . Lymph node metastasis was detected in 21 % (6/28) of patients who underwent R0 resection and in 9 % (1/11) of those who underwent R1 resection (P = 0.34). There was no significant difference in disease-free survival between patients who underwent R0 versus those who underwent R1 resection (P = 0.33) (Fig. 3b ).
Recurrence and margin status
Next, we examined the relationship between cancer recurrence pattern (sites) and surgical margin status, because the survival of patients with IHCC has been reported to correlate strongly with surgical margin status [16] . The negative margin width was examined in 28 patients who underwent R0 resection. The median margin width was 1 mm (range 0-40 mm), and only five patients had margins [10 mm. Table 3 shows the initial recurrence sites and negative surgical margin widths, including the site of distant recurrence. Local recurrence was defined as a tumor that recurred within 10 mm from the surgical margin. The rate of local recurrence was higher in patients with R1 resection (55 %, 6/11) than in those with R0 resection (11 %, 3/28) (P = 0.008). With regard to surgical margin width, patients with margins B5 mm versus [5 mm showed similar patterns and rates of recurrence (P = 0.93). In patients with R0 resection, there was no significant difference in either the disease-free survival rate (44 vs. 42 %, P = 0.87) or cumulative survival rate (63 vs. 75 %, P = 0.77) at 3 years between patients with narrow (B5 mm) versus wide ([5 mm) margins, respectively. 
Discussion
The prognosis of patients with resected IHCC remains unsatisfactory, despite progress in aggressive surgical treatments [2] . After surgical resection, the reported recurrence rate is 55-72 % [7] [8] [9] [10] [17] [18] [19] [20] . The current study showed a similar recurrence rate (56 %). A possible reason for the poor prognosis may be the lack of a standardized optimal surgical protocol for resecting IHCC. For example, the need for lymphadenectomy and adequate surgical margin width remains to be determined. Therefore, we examined the prognostic factors and the impact of a negative surgical margin width in patients with resected IHCC, based on our 13-year experience. We confirmed that residual tumor status (R0/1 resection) is an important predictor of long-term survival.
Curative surgical resection is the most effective treatment for IHCC. The beneficial impact of R0 resection is completely recognized; however, the influence of R1 resection on survival is controversial. Several published reports have suggested that R1 resection is an important prognostic factor associated with poorer survival [3, 4, 8, [21] [22] [23] [24] . In this study, the survival of patients who underwent R0 or R1 resection was significantly better than that of those who underwent R2 resection. While the survival rate of patients who underwent R0 resection tended to be higher than that of those who underwent R1 resection, the difference did not reach statistical significance, probably due to the small patient numbers. Another reason for this result may be the higher rate of lymph node metastasis in patients who underwent R0 resection (21 %) than that in those who underwent R1 resection (9 %). Different rates of lymph node metastasis might make the survival curve of R0 patients more closely match that of R1 patients, because lymph node metastasis is recognized as a powerful prognostic factor [3] [4] [5] . In this study, the overall rate of lymph node metastasis in the patients who underwent resection was 25 %, similar to that reported in previous papers (14-40 %) [4, 5, 16, 24] . Interestingly, recent reports suggest that for patients without lymph node metastasis, a positive surgical margin is an important prognosis factor, although for patients with lymph node metastasis, a positive margin is not a prognostic factor [3, 16] . Our results clearly demonstrated that R1 resection is associated with a better prognosis than R2 resection; therefore, R1 resection could be appropriate when R0 resection cannot be achieved.
We examined surgical margin width in patients with R0 resection because the influence of resection margin on outcome has also been controversial. Patients with narrow or wide negative margins showed similar recurrence patterns, reflecting the results of previous papers [10, 25, 26] . In contrast, a recent paper reported that margin width and prognosis correlated linearly in patients without lymph node metastasis, and [10 mm could be considered a safe surgical margin [16] . Other papers similarly suggested that curative resection requires a clear margin of 10 mm [14, 27] . With regard to surgical margins, there is an interesting report that mutations of the APC or KRAS gene were detected even 4 mm from the macroscopic tumor border in patients with liver metastasis of colorectal adenocarcinoma [28] . This finding raises the possibility that tumor may remain in cases of a narrow margin width. However, a multi-institutional analysis recently showed that survival was not influenced by the width of a negative resection margin [29] .
While there were many cases of local recurrence with R1 resection, the most common sites of recurrence after R0 resection were distant in this study. Shimada et al. [25] and Tamandl et al. [10] also reported that residual tumor status (R0 or R1) did not correlate with the recurrence site and that there were distant metastases, such as in the liver or lymph nodes. This suggests that resection should be performed even if a wide negative margin is difficult to achieve.
The current study did not confirm the impact of lymph node metastasis on survival. This atypical finding is probably due to the different surgical procedures used for sampling of the lymph nodes, without performing systematic lymphadenectomy. The significance of systematic lymphadenectomy is still unknown. Previous reports have indicated that lymphadenectomy improved survival, with findings based on the macroscopic classification or the numbers or sites of lymph node metastases [22, 30, 31] . However, only a few reports have compared the survival of patients with IHCC with lymphadenectomy versus without lymph nodes (n = 3), liver (n = 2), lung (n = 2), bone (n = 2), peritoneum (n = 2), and unknown (n = 1) b liver metastasis c two R1 patients showed positivity for both bile duct and liver parenchyma lymphadenectomy [2, 15, 24] . These reports concluded that routine systematic lymphadenectomy is of limited value and do not recommend it. Further prospective studies are required to resolve this issue.
Our univariate analysis revealed that elevated CA19-9 is an important prognostic factor after surgical resection, as suggested in other recent reports [7] [8] [9] [10] . However, when examining the prognostic value of CA19-9, various investigators used different cut-off point for CA19-9 [9, 10, 19] . In the current study, we set the cut-off for CA19-9 at 200 U/ml, consistent with the report by Cho et al. [14] . If we had used a CA19-9 cut-off of C625 U/ml, which was found by ROC analysis, the 2-year survival rate for our patients with this more highly elevated CA19-9 would have been 0 %. We used the 200 U/ml for the cut-off point of CA19-9 for multivariate analysis in this study because too few patients had a CA19-9 level C625 U/ml. In contrast, some investigators reported that CA19-9 was not a prognostic factor based on setting the CA19-9 cut-off at 37 or 40 U/ml [7, 32, 33] . Because a previous study found that CA19-9 was associated with tumor size and lymph node metastasis [23] , an extremely high CA19-9 level may be suggestive of progression like lymph node metastasis or dissemination.
Another factor predicting survival was pathological differentiation. However, we were only able to confirm this after surgery and surgeons do not remedy it. If the histological diagnosis based on preoperative biopsy is not welldifferentiated adenocarcinoma, patients could be a candidate for neo-adjuvant chemotherapy. However, the risk of dissemination was previously reported [34] . We should positively consider adjuvant chemotherapy for these patients because their prognosis is poor, although there are very few reports about adjuvant treatment for IHCC. In the present study, selected patients received chemotherapy with GEM, but our retrospective analysis did not show that GEM had a significant impact on the survival of patients with resected IHCC. Shinohara et al. [35] reported that adjuvant radiation therapy after surgery could improve median overall survival compared with surgery or radiation alone. Murakami et al. [36] reported that GEM-based adjuvant chemotherapy was effective for cholangiocarcinoma, including IHCC. Shen et al. [37] found that adjuvant transcatheter arterial chemoembolization with fluorouracil or carboplatin, epirubicin, and hydroxycamptothecin did not improve recurrence-free survival, but it prolonged overall survival. Although further prospective investigation is required, our data suggest that a drug other than GEM or combination chemotherapy should be considered for patients with resected IHCC.
This study has some limitations. It was retrospective and the sample size was small. Moreover, we did not perform systematic lymphadenectomy and there may be a selection bias in adjuvant chemotherapy. Therefore, further studies on a large number of patients are necessary to evaluate the prognostic factors about IHCC more accurately.
In conclusion, residual tumor status and pathological tumor differentiation are significant prognostic factors for long-term survival after resection of IHCC. R0/1 resection can improve the survival of patients with IHCC. R1 resection was associated with a higher risk of local recurrence than R0 resection. In R0 resection, negative surgical margin width did not affect the patterns and rates of recurrence, so these patients should be carefully monitored for possible distant metastasis, rather than just local recurrence, during follow-up.
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